Hansoh Pharmaceutical Group Company Limited
3692
Rank in Stocks
#970
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Share Price
$4.06
Last synced: 2026-10-16
Market Cap
$24.62B
Change (1 day)
1.15%
Change (1 year)
-13.54%
Country
CN
Trade Hansoh Pharmaceutical Group Company Limited (3692)
Category
Healthcare
Operating Margin for Hansoh Pharmaceutical Group Company Limited (3692)
Operating Margin as of October 2026 TTM: 37.52%
According to Hansoh Pharmaceutical Group Company Limited latest financial reports and stock price the company's current Operating Margin (TTM) is 37.52%. At the end of 2023 the company had an Operating Margin of 28.10%.
Operating Margin history for Hansoh Pharmaceutical Group Company Limited from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 37.52% | 14.11% |
| 2024 | 32.88% | 17.01% |
| 2023 | 28.10% | -1.30% |
| 2022 | 28.47% | -2.33% |
| 2021 | 29.15% | -8.65% |
| 2020 | 31.91% | -0.34% |
| 2019 | 32.02% | 6.56% |
| 2018 | 30.05% | -3.62% |
| 2017 | 31.18% | -6.28% |
| 2016 | 33.27% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -99.39% |
IN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.